secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-05-12T20:06:30+00:00
Accession:  0001404644-26-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028
--------------------------------------------------------------------------------

- Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.
- ~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.
- Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.
- Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.
- Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/0001404644-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/ngne-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer